Associate Professor, Medicine, University of Colorado School of Medicine
Oncology
Dr. Antonio Jimeno, MD
|
|
Give Review
Dr. Antonio Jimeno works in the field of Oncology. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Antonio Jimeno is a published doctor and has 40 publications published. The lastest was: 'Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base.' Antonio Jimeno accepts Medicare payments and is listed with Medicare.gov.
Publications
- Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous Cell carcinoma.
- A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous Cell carcinoma.
- A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metast...
- A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer.
- A phase I first-in-human study of enoticumab (REGN421), a fully-human Delta-like ligand 4 (Dll4) monoclonal antibody in patients with advanced solid tumors.
- A Phase I, dose-finding study in patients with advanced solid malignancies of the Oral γ-secretase inhibitor PF-03084014.
- A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
- Pembrolizumab: PD-1 inhibition as a therapeutic strategy in Cancer.
- Nivolumab.
- A randomized, phase 2 trial of cetuximab with or without PX-866, an irreversible Oral phosphatidylinositol 3-kinase Inhibitor, in patients with relapsed or metastatic ...
- Panitumumab in the treatment of colon Cancer: A biomarker dilemma.
- Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous Cancers.
- Targeting the Wnt pathway in human Cancers: Therapeutic targeting with a focus on OMP-54F28.
- A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic coloRectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
- Belinostat for the treatment of peripheral T-Cell lymphomas.
- Novel treatments for head and neck squamous Cell carcinoma: preclinical identification and clinical investigation.
- Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle Cell lymphoma.
- Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.
- Phase 1 study of Oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
- Afatinib for the treatment of patients with EGFR-positive non-small cell lung Cancer.
- A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.
- The dual pathway inhibitor rigosertib is effective in direct-patient tumor xenografts of head and neck squamous Cell carcinomas.
- Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
- Dabrafenib in the treatment of advanced melanoma.
- Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
- A patient tumor transplant model of squamous cell Cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
- Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck Cancer.
- Phase 1 Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors.
- The development of regorafenib and its current and potential future role in Cancer therapy.
- Vismodegib in Basal cell carcinoma.
- JAK2 inhibition for the treatment of hematologic and solid Malignancies.
- Patient-derived tumour xenografts as models for oncology drug development.
- Crizotinib for the treatment of patients with advanced non-small cell lung Cancer.
- Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors...
- A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung Cancer.
- KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in coloRectal cancer: practical application of patient selection.
- Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
- Expansion of Human and Murine Hematopoietic Stem and Progenitor Cells Ex Vivo without Genetic Modification Using MYC and Bcl-2 Fusion Proteins.
- Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck Cancer according to the National Cancer Data Base.
Schools
Johns Hopkins University Program
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Hospital
-
University of Colorado Hospital
Drug Facts
| NPI NUMBER | 1508039991 | |
| NPPES Provider LastName | JIMENO | |
| NPPES Provider FirstName | ANTONIO | |
| NPPES Provider ZIPCode | 800452545 | |
| NPPES Provider State | CO | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 179.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 34.0 | |
| Percent Opioid Claims | 18.99 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1508039991 |
| Last Name Of The Provider | JIMENO |
| First Name Of The Provider | ANTONIO |
| View All |
Similar Doctors
|
Dr. Paul A. Bunn Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. William E. Daniel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Elaine T. Lam, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Stephen Leong, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. L Michael Glode, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Daniel W. Bowles, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sami G. Diab, MD
This Doctor is OpenDoctor Recommended.
|